Conference abstract · 25 May 2017
Review articlePublished 8 Feb 2018
Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Diffuse large B-cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma (NHL) cases and 20,000 deaths have been estimated in the United States for 2010. In spite of novel therapeutic options have been suggested and successfully tried in patients with lymphoproliferative disorders, the standard first- line treatment for DLBCL has remained the same combination of chemotherapy and CD20 (activated-glycosylated phosphoprotein) targeting monoclonal antibody rituximab (R) with 30% to 40% chance of relapse after first line R-CHOP treatment. Several clinical trials have been designed to evaluate safety, efficacy and superior clinical benefit by adding novel agents, intensifying cycles of treatment or substituting rituximab with new CD20 targeting immunotherapies. Intensification of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy from 3- week interval cycles to 2- week interval cycles has already shown clinical benefit in a German trial but failed to show improved overall and disease free (DFS1) survival in both elderly (60 to 80 years) and young patients in randomized phase 3 clinical trials. Namely, in a phase 2 randomized clinical trials (PYRAMID) as a first line treatment for non- Germinal Center Cell (GCB) subtype of DLBCL the results were in favor of R-CHOP and adding bortezomib was not found to improve DFS and OS significantly. Immunomodulatory agent lenalidomide is another attractive therapeutic option for non-GCB subtype of DLBCL. Statistically significant difference between non-GCB and GCB controls treated with standard R-CHOP alone in terms of progression-free survival (28% vs. 64%; P = 0.00029) and overall survival (46% vs. 74%; P = 0.000036) was reported while non-GCB and GCB treated with R-CHOP plus lenalidomide had similar rates of progression (60% vs. 59%; P = 0.83) and overall survival at 2 years (83% vs. 75%; P = 0.61). Despite these promising clinical results, further clinical studies, especially phase 3 randomized clinical trials are required to confirm the alternate competitive treatment for DLBCL patients.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2018
Cost-Utility of PET/CT Surveillance Post Achieving First Remission in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review
Research article · 2018
Voluminous and Vesicular: Diffuse Large B Cell Lymphoma (DLBCL)
Case report · 10 Apr 2024
Lacrimal Sac Diffuse Large B-Cell Lymphoma Presenting as Sudden Onset Binocular Diplopia: A Case Report
Commentary · 28 Jun 2023
Overcoming Immune Resistance in Diffuse Large B-Cell Lymphoma: Targeting Escape Mechanisms for Effective Immunotherapy
More from this journal
The newest in Archives in Cancer Research.
Perspective · 20 Dec 2024
Radiotherapy: Advances, Mechanisms, and Applications in Cancer Treatment
Perspective · 20 Dec 2024
Chemotherapy: A Vital Treatment in the Battle Against Cancer
Perspective · 20 Dec 2024
Tumor Microenvironment: A Key Determinant of Cancer Progression
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives in Cancer Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Timothey Allen”
- BylineArticles whose byline prints “Ghazaleh-Shoja E Razavi”
- BylineArticles whose byline prints “Nepton Sheikh Khoni”
- BylineArticles whose byline prints “Naveed Basha”

